25.12.2020 Views

Medikal Teknik December 2020

Medikal Teknik December 2020

Medikal Teknik December 2020

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

48<br />

Eskiçorapçı, said, “According to the data of the Prostate<br />

Cancer Database of the Turkish Association of Urooncology,<br />

laparoscopic or robot-assisted laparoscopic surgery method<br />

is applied in approximately one third of the patients who<br />

undergo radical prostatectomy surgery. Considering the<br />

distribution over the years, it is seen that the number<br />

of open surgery is stable, but there is an increase in the<br />

number of laparoscopic or robot-assisted laparoscopic<br />

surgeries,” and he added more, “It is beneficial for patients<br />

to seek an experienced and reliable surgeon rather than a<br />

technique for their treatment. Targeted ‘Focal Therapies’<br />

based on imaging instead of treating the whole organ will<br />

stand out in the near future.”<br />

Referring to the effect of the COVID-19 epidemic on<br />

prostate cancer treatments, Assoc . Dr. İlker Tinay said,<br />

“As the Turkish Association of Urooncology, we made<br />

recommendations regarding the applications for the<br />

diagnosis and treatment of prostate cancer during the<br />

COVID-19 pandemic in the light of scientific data with the<br />

guide we shared with our colleagues during the epidemic<br />

process. In general, in this process, while the delayed<br />

approach in the treatment of early stage disease that was<br />

newly diagnosed before the epidemic was at the forefront,<br />

in the presence of advanced stage disease, the approach<br />

of not delaying the treatments was recommended.”<br />

There is no report from both the Ministry of Health and<br />

our association database on the extent to which prostate<br />

cancer diagnosis and treatment in our country are affected<br />

by the COVID-19 epidemic. However, in the 30-day period<br />

after the first reported case in our country (between 11<br />

March and 11 April <strong>2020</strong>), the study on how the daily<br />

urooncological practice was affected and contributed by<br />

the researchers who are members of our association was<br />

published in the Gold Urology Journal. In this study, which<br />

was carried out jointly by urology clinics in 5 university<br />

hospitals in different geographical regions, a comparison<br />

was made with urological cancer surgeries in the same<br />

date range in 2019. This study showed that the number of<br />

radical surgeries performed with the diagnosis of prostate<br />

cancer decreased by half in the specified period, but in<br />

accordance with the guideline recommendation, there was<br />

no disruption in the treatment of high-risk patients and the<br />

treatment of this group of patients who should not expect<br />

continues.<br />

Pharm. Serkan Barış, Country Presıdent, Astrazeneca<br />

Pharmaceuticals Turkey, made the following statement<br />

on the report, “Prostate Cancer Map of Turkey Report<br />

contains important information about the effects of early<br />

diagnosis of the disease on patient health in the diagnosis<br />

and treatment of prostate cancer, which is among the most<br />

common types of cancer both in our country and worldwide<br />

in addition to the important developments in recent<br />

years. As AstraZeneca Turkey, we are delighted to provide<br />

unconditional support to this meaningful study, which we<br />

believe will increase awareness of prostate cancer and its<br />

effects.”<br />

Serkan Barış, Country President,<br />

Astrazeneca Pharmaceuticals Turkey<br />

bölgelerdeki 5 üniversite hastanesini üroloji kliniklerinin<br />

ortak gerçekleştirdiği bu çalışmada, 2019 yılında aynı tarih<br />

aralığında ürolojik kanser cerrahileri ile karşılaştırma<br />

yapıldı. Bu çalışma, belirtilen dönemde prostat kanseri<br />

tanısı ile yapılan radikal cerrahilerin sayısının yarı yarıya<br />

azaldığını ancak kılavuz önerisi ile uyumlu olarak yüksek<br />

riskli hastaların tedavisinde aksama olmadığını ve bu<br />

beklememesi gereken hasta grubunun tedavisinin devam<br />

ettiğini gösterdi.<br />

AstraZeneca Türkiye Ülke Başkanı Ecz. Serkan Barış<br />

raporla ilgili şu açıklamayı yaptı: “Türkiye Prostat Kanseri<br />

Haritası Raporu, gerek ülkemizde gerekse dünya genelinde<br />

en sık görülen kanser türleri arasında yer alan prostat<br />

kanserinin tanı ve tedavisinde son yıllarda yaşanan önemli<br />

gelişmelerin yanı sıra hastalığın erken tanısının hasta<br />

sağlığı üzerinde meydana getirdiği etkilere dair önemli<br />

bilgiler içeriyor. AstraZeneca Türkiye olarak prostat<br />

kanserine ve etkilerine dair farkındalığı artıracağına<br />

inandığımız bu anlamlı çalışmaya koşulsuz destek olmaktan<br />

büyük bir mutluluk duyuyoruz.”<br />

Aralık - <strong>December</strong> <strong>2020</strong>

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!